Inducible cell death systems
AssigneeSenti Biosciences, Inc.
InventorsRocky CHEUNG, Russell Morrison GORDLEY, Timothy Kuan-Ta LU, Michelle Elizabeth HUNG, Rebecca Tayler COTTMAN
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for inducing cell death in a regulated manner, for example in a safety switch system. Inducible cell death can be triggered by ligand binding to a one or more ligand binding domains. Cell death can include induction of apoptosis.
Claims21
1-20. (canceled)
A method of treating a subject in need thereof, comprising:
- delivering to the subject in need thereof a therapeutically effective amount of an engineered cell comprising an inducible cell death system or an engineered nucleic acid comprising the inducible cell death system,
- wherein the inducible cell death system comprises two or more polypeptide monomers, wherein each polypeptide monomer comprises one or more ligand binding domains and a cell death-inducing domain, wherein the polypeptide monomers are configured to oligomerize upon contacting the polypeptide monomers with a cognate ligand of the one or more ligand binding domains and generate a cell-death inducing signal in a cell in which the polypeptide monomers are expressed, and wherein:
- i. each polypeptide monomer of the two or more polypeptide monomers comprises the same ligand binding domain, wherein the same ligand binding domain comprises a domain or functional fragment thereof selected from the group consisting of:
- a hormone-binding domain of estrogen receptor (ER) domain, optionally comprising the amino acid sequence of SEQ ID NO:
- 42;
- an ABI domain, optionally comprising the amino sequence of SEQ ID NO:
- 31;
- a PYL domain, optionally comprising the amino acid sequence of SEQ ID NO:
- 53;
- a caffeine-binding single-domain antibody, optionally comprising the amino acid sequence of SEQ ID NO:
- 33;
- a cannabidiol binding domain, optionally comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 34, 35, 36, 37, and 38;
- a heavy chain variable region (VH) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:
- 50, and/or the light chain variable region (VL) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:
- 51;
- optionally comprising the amino acid sequence of SEQ ID NO:
- 43;
- a progesterone receptor domain, optionally comprising the amino acid sequence of SEQ ID NO:
- 52;
- and combinations thereof;
- or
- ii. a first polypeptide monomer of the two or more polypeptide monomers comprises a first ligand binding domain, a second polypeptide monomer of the two or more polypeptide monomers comprises a second ligand binding domain, and wherein the second ligand binding domain is different from the first ligand binding domain.
A pharmaceutical composition comprising:
- a) an inducible cell death system, an engineered nucleic acid encoding the inducible cell death system, or an engineered cell comprising the inducible cell death system, wherein the inducible cell death system comprises two or more polypeptide monomers, wherein each polypeptide monomer comprises one or more ligand binding domains and a cell death-inducing domain, wherein the polypeptide monomers are configured to oligomerize upon contacting the polypeptide monomers with a cognate ligand of the one or more ligand binding domains and generate a cell-death inducing signal in a cell in which the polypeptide monomers are expressed, and wherein:
- i) each polypeptide monomer of the two or more polypeptide monomers comprises the same ligand binding domain, wherein the same ligand binding domain comprises a domain or functional fragment thereof selected from the group consisting of:
- a hormone-binding domain of estrogen receptor (ER) domain, optionally comprising the amino acid sequence of SEQ ID NO:
- 42;
- an ABI domain, optionally comprising the amino sequence of SEQ ID NO:
- 31;
- a PYL domain, optionally comprising the amino acid sequence of SEQ ID NO:
- 53;
- a caffeine-binding single-domain antibody, optionally comprising the amino acid sequence of SEQ ID NO:
- 33;
- a cannabidiol binding domain, optionally comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 34, 35, 36, 37, and 38;
- a heavy chain variable region (VH) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:
- 50, and/or the light chain variable region (VL) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO:
- 51;
- optionally comprising the amino acid sequence of SEQ ID NO:
- 43;
- a progesterone receptor domain, optionally comprising the amino acid sequence of SEQ ID NO:
- 52;
- and combinations thereof;
- or
- ii) a first polypeptide monomer of the two or more polypeptide monomers comprises a first ligand binding domain, a second polypeptide monomer of the two or more polypeptide monomers comprises a second ligand binding domain, and wherein the second ligand binding domain is different from the first ligand binding domain;
- and
- b) a pharmaceutically acceptable carrier.
An inducible cell death system comprising an activation-conditional control polypeptide (ACP),
- wherein the ACP comprises a ligand binding domain and a transcriptional effector domain, and
- wherein upon binding of the ligand binding domain to a cognate ligand, the ACP is capable of modulating transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter,
- wherein the gene of interest comprises a cell death inducing polypeptide.
A multimeric activation-conditional control polypeptide (ACP) comprising:
- a) a first chimeric polypeptide, wherein the first chimeric polypeptide comprises a first ligand binding domain and a transcriptional activation domain;
- and
- b) a second chimeric polypeptide, wherein the second chimeric polypeptide comprises a second ligand binding domain and a nucleic acid-binding domain,
- wherein the first chimeric polypeptide and the second chimeric polypeptide oligomerize to form the multimeric ACP via a cognate ligand that binds to each ligand binding domain, and wherein the multimeric ACP is capable of inducing transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter,
- wherein the gene of interest is a cell death-inducing polypeptide, optionally wherein the cell death-inducing domain is derived from a protein selected from the group consisting of:
- caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, Diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), a TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondria-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, p53-upregulated modulator of apoptosis (PUMA), Noxa, Blk, Hrk, Cytochrome c, Arts, TNF-related cell death-inducing ligand (TRAIL), Herpes Simplex Virus thymidine kinase (HSV-TK), Varicella Zoster Virus thymidine kinase (VZV-TK), viral Spike protein, Carboxyl esterase, cytosine deaminase, nitroreductase Fksb, Carboxypeptidase G2, Carboxypeptidase A, Horseradish peroxidase, Linamarase, Hepatic cytochrome P450-2B 1, and Purine nucleoside phosphorylase, optionally wherein the caspase 9 or a functional truncation thereof, comprises the amino acid sequence of SEQ ID NO:
- 39, optionally wherein the DTA comprises the amino acid sequence of SEQ ID NO:
- 41, optionally wherein the granzyme B comprises the amino acid sequence of SEQ ID NO:
- 47, optionally wherein the Bax comprises the amino acid sequence of SEQ ID NO:
- 32, and wherein the transcriptional activation domain is selected from the group consisting of:
- a Herpes Simplex Virus Protein 16 (VP16) activation domain;
- an activation domain comprising four tandem copies of VP16;
- a VP64 activation domain;
- a p65 activation domain of NFκB;
- an Epstein-Barr virus R transactivator (Rta) activation domain;
- a tripartite activator comprising the VP64, the p65, and the Rta activation domains (VPR activation domain);
- a tripartite activator comprising the VP64, the p65, and the HSF1 activation domains (VPH activation domain);
- and a histone acetyltransferase (HAT) core domain of the human E1A-associated protein p300 (p300 HAT core activation domain).
Dependencies are inferred from the claim text.